Oruka Therapeutics, Inc. ORKA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $109.86M-21.2% | $100.64M-19.2% | $148.06M+198% | $144.76M+497% | $139.35M+2,296% | ||
| $23.54M-5.1% | $21.41M+0.5% | $27.68M+183% | $26.32M+244% | $24.8M+279% | ||
| $133.4M-18.7% | $122.05M-16.4% | $175.74M+196% | $171.09M+437% | $164.15M+1,228% | ||
| -$133.4M+18.7% | -$122.05M+16.4% | -$175.74M-196% | -$171.09M-437% | -$164.15M-1,228% | ||
| $17.15M+100% | $16.62M+290% | $16.17M— | $13.17M— | $8.56M— | ||
| -$116.25M+25.3% | -$105.43M+25.6% | -$159.57M-170% | -$157.92M-396% | -$155.59M-1,306% | ||
| -$133.29M+18.8% | -$121.97M+16.4% | -$175.66M-196% | -$171.01M-437% | -$164.09M-1,229% | ||
| -$133.4M+18.7% | -$122.05M+16.4% | -$175.74M-196% | -$171.09M-437% | -$164.15M-1,228% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Oruka Therapeutics, Inc. profitable?
- Oruka Therapeutics, Inc. is not currently profitable: it reported a net loss of $116.3M over the trailing twelve months.
- What is Oruka Therapeutics, Inc.'s earnings per share?
- Oruka Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-6.19.
- Where does Oruka Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.